首页> 外文期刊>Journal of Medicinal Chemistry >Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII
【24h】

Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII

机译:基于金属茂的癌症相关碳酸酐酶IX和XII抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

In this study, 20 metallocene-based compounds comprising extensive structural diversity were synthesized and evaluated as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. These compounds proved moderate to good CA inhibitors in vitro, with several compounds displaying selectivity for cancer-associated isozymes CA IX and CA XII compared to off-target CA I and CA II. Compound 6 was the most potent ferrocene-based inhibitor with K _is of 5.9 and 6.8 nM at CA IX and XII, respectively. A selection of key drug-like parameters comprising Log P, Log D, solubility, and in vitro metabolic stability and permeability were measured for two of the ferrocene-based compounds, regioisomers 1 and 5. Compounds 1 and 5 were found to have characteristics consistent with lipophilic compounds, however, our findings show that the lipophilicity of the ferrocene moiety is not well modeled by replacement with either a naphthyl or a phenyl moiety in software prediction tools.
机译:在这项研究中,合成了20种具有广泛结构多样性的基于茂金属的化合物,并将其评估为碳酸酐酶(CA,EC 4.2.1.1)抑制剂。这些化合物在体外证明是中度至良好的CA抑制剂,与脱靶CA I和CA II相比,几种化合物对癌症相关同工酶CA IX和CA XII具有选择性。化合物6是最有效的二茂铁基抑制剂,在CA IX和XII的K值分别为5.9和6.8 nM。测量了两种基于二茂铁的化合物区域异构体1和5的关键药物样参数的选择,包括Log P,Log D,溶解度以及体外代谢稳定性和通透性。发现化合物1和5具有一致的特性但是,我们的发现表明,用亲脂性化合物处理二茂铁部分的亲脂性并不能通过软件预测工具中的萘基或苯基部分取代来很好地建模。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号